Eli Lilly's newly launched weight-loss pill, Foundayo, is set to transform the competitive landscape for obesity medications, directly challenging Novo Nordisk's dominant Wegovy. While Lilly's product has garnered significant prescriptions following its FDA approval, Novo Nordisk maintains an advantage with its drug's superior performance in clinical analyses. This evolving rivalry underscores the pressing need for continual innovation as both companies vie for market share in the high-stakes obesity treatment sector.
Loading timeline…
